ORBIT Secures $38.

Quantis

Quantis, part of BCG, is a sustainability consulting firm that helps organizations translate sustainability ambition into measurable business value. With over 20 years of experience and roots in environmental science, we combine data-driven insight and strategic expertise to support the integration of sustainability into strategy, operations, and performance. Working across industries, we help organizations reduce risk, improve efficiency, drive innovation, and strengthen competitive positioning. Together with BCG, we help scale sustainability solutions across enterprises and value chains.

BioTechX

BioTechX successfully brings together an amalgamation of genomics, translational medicine, data scientists, IT, bioinformaticians, cheminformaticians, clinicians, healthcare and pharma companies. The event will showcase innovation, demonstrate success and break through the obstacles and barriers to ensure that the innovations in genomics and big data, enter the clinic with speed and efficiency. BioTechX Europe 6-8 October 2025, Basel BioTechX Europe is Europe’s largest congress covering diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare. Since 2018 we have re-established our presence in Europe and run the event in Basel annually. In 2026, the event will return to the Messe Basel from 6-8th October. Follow us on @BioTechX USA to stay updated on BioTechX USA 2026.

goNEON

goNEON uses agentic AI to generate regulation-compliant infrastructure and mobility plans in minutes instead of months. We help cities, planners, and operators replace slow, manual planning with fast, scalable, city-wide decision-making.

CCRAFT

CCRAFT is shaping the future of photonic integrated circuits (PICs) with advanced thin-film lithium niobate (TFLN) technology. As a dedicated open-access foundry, built on years of pioneering R&D at the Swiss Center for Electronics and Microtechnology (CSEM), we combine technological innovation with market-driven solutions—addressing current industry needs while paving the way for next-generation PIC platforms. We offer monolithic TFLN PICs, TFLN chiplets for heterogeneous integration, and processing of TFLN-enhanced silicon photonic wafers, solving critical challenges in optical communications, high-performance computing (HPC), AI, Quantum, space technologies, optical computing, and advanced sensing. To meet the growing demand for high-volume, high-performance photonic solutions, we are scaling up manufacturing in our cleanroom facility. Our comprehensive process design kits (PDKs) empower customers to confidently design and develop robust, cutting-edge PIC products tailored to their specific applications. At CCRAFT, we bridge technological innovation with market needs, ensuring our solutions create lasting impact across diverse industries. Join us as we craft the future of photonics—at the speed of light.

Cria Technologies

Crìa is reinventing cold-chain logistics with breakthrough high-vacuum insulation technology. We are introducing a new class of containers for temperature-controlled transport in pharma and biotech, up to ten times more effective than existing solutions, while offering the first portable options for personal transport (cabin-bag compliant) and the most compact, ultra-light shipping solutions. This enables safer, longer, and more sustainable transport at refrigerated, ultra-low, and cryogenic temperatures (down to –150 °C). Our innovation builds on unique know-how in high-vacuum technology, drawing from particle physics research, solar thermal systems, and space exploration. By drastically reducing reliance on dry ice and liquid nitrogen, both carbon-intensive to produce and hazardous to transport, we deliver a step-change in sustainability. Our technology also unlocks the use of Phase Change Materials, enabling reusable and eco-friendly alternatives to traditional coolants. Crìa is not only redefining performance and safety in the cold chain, but also enabling the next wave of innovation: from personalized medicine and cell & gene therapies to in vitro fertilization, biodiversity preservation, collaborative research, and humanitarian logistics.